Kindeva Drug Delivery has announced that it will install a second LGWP propellant MDI manufacturing line at its facility in Loughborough, UK. The company’s first LGWP line at Loughborough is expected to be completed by the end of this year. Kindeva The new line, which will fill both HFA-152a and HFO-1234ze(e), is expected to come on line in 2026.
In August 2023, Kindeva said that it had received a grant from the UK’s Life Sciences Innovation Manufacturing Fund that would go toward increasing its LGWP MDI manufacturing capacity. Later that year, Kindeva announced a partnership with HFA-152a manufacturer Koura Global for conversion of an existing MDI to the LGWP propellant.
Kindeva CEO Milton Boyer commented, “This investment will bring to the market one of the first large-volume commercial green propellant lines to the contract manufacturing market capable of supplying up to 50 million pMDI units per year. This second investment in low-GWP GMP manufacturing capacity further underscores Kindeva’s commitment to enable the pharmaceutical industry to meet its sustainability goals, whilst ensuring patient choice is not compromised. With our first GMP low-GWP manufacturing line expected to be operational in 2024, we are proud to be leading the transition to low-GWP propellants by ensuring the capacity is available.”
Read the Kindeva Drug Delivery press release.
